Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GenSci164 in Healthy Adult Participants in China
NCT07790783Phase 1Not yet recruiting
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Aug 2026
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing GenSci164 Injection with Placebo (2 arms). Primary endpoint: Adverse Events up to 113 days. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
GenSci164
Beyond the preview
Go deeper on NCT07790783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07790783.